株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

開放隅角緑内障(OAG)- 市場洞察、疫学、市場予測 2028年

Open-angle glaucoma (OAG) - Market Insights, Epidemiology, and Market Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 780420
出版日 ページ情報 英文 316 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.16円で換算しております。
Back to Top
開放隅角緑内障(OAG)- 市場洞察、疫学、市場予測 2028年 Open-angle glaucoma (OAG) - Market Insights, Epidemiology, and Market Forecast - 2028
出版日: 2019年11月01日 ページ情報: 英文 316 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)における開放隅角緑内障(OAG)の2017年の罹患数は981万9,080人、同年の市場規模はおよそ33億1,670万米ドルと推計されています。

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)における開放隅角緑内障(OAG)市場を調査し、疾病の概要や現行の治療法、上市済み治療薬および新薬のプロファイル、全体および各国の市場動向、疫学的予測、市場規模、有病数・罹患数の推移と予測、アンメットニーズ、市場の成長要因および障壁などを包括的にまとめています。

目次

第1章 重要洞察

第2章 開放隅角緑内障(OAG)市場の概要

  • 開放隅角緑内障(OAG)の市場シェア(実績値)
  • 開放隅角緑内障(OAG)の市場シェア(予測値)

第3章 疾病背景と概要:開放隅角緑内障(OAG)

  • イントロダクション
  • 分類
  • 兆候と症状
  • リスク要因
  • 臨床症状
  • 遺伝的基盤
    • ミオシリン(MYOC, OMIM #601652)
    • オプチニューリン(OPTN, OMIM #602432)
    • TANK結合キナーゼ-1(TANK-binding Kinase-1)
    • WDリピート36(WDR36, OMIM 609669)
  • 診断

第4章 疫学と患者人口

  • 主な調査結果
  • 主要7カ国の緑内障の総有病数
  • 主要7カ国の開放隅角緑内障(OAG)の総有病数

第5章 米国の開放隅角緑内障(OAG)の疫学

  • 仮定と理論的根拠
  • 開放隅角緑内障(OAG)の有病数
  • 開放隅角緑内障(OAG)の有病数:性別
  • 開放隅角緑内障(OAG)の有病数:年齢別
  • 開放隅角緑内障(OAG)の有病数:病型別

第6章 EU5カ国の開放隅角緑内障(OAG)の疫学

  • 仮定と理論的根拠
  • ドイツ
    • 仮定と理論的根拠
    • 開放隅角緑内障(OAG)の有病数
    • 開放隅角緑内障(OAG)の有病数:性別
    • 開放隅角緑内障(OAG)の有病数:年齢別
    • 開放隅角緑内障(OAG)の有病数:病型別
  • フランス
  • イタリア
  • スペイン
  • 英国

第7章 日本の開放隅角緑内障(OAG)の疫学

  • 仮定と理論的根拠
  • 開放隅角緑内障(OAG)の有病数
  • 開放隅角緑内障(OAG)の有病数:性別
  • 開放隅角緑内障(OAG)の有病数:年齢別
  • 開放隅角緑内障(OAG)の有病数:病型別

第8章 治療アルゴリズム・現行治療

  • 治療アルゴリズム
  • 治療と管理
    • 治療の基礎
    • 治療の選択肢
    • 投薬治療
    • レーザー線維柱帯形成術
    • 外科的治療
  • 重度または不可逆的視力喪失患者の管理

第9章 アンメットニーズ

第10章 上市済み治療薬

  • 上市済み治療薬と薬効分類
  • ROCKLATAN:Aerie Pharmaceuticals
    • 医薬品概要
    • 規制のマイルストーン
    • 臨床動向
    • 安全性と有効性
    • 製品プロファイル
  • Rhopressa:Aerie Pharmaceuticals
  • XELPROS (latanoprost ophthalmic emulsion) 0.005%:Sun Pharma Advanced Research Company Limited
  • エイベリス点眼液0.002%:参天製薬・宇部興産
  • VYZULTA: Bausch and Lomb
  • タプコム配合点眼液(DE-111):参天製薬
  • グラナテック:D.Western Therapeutics Institute (DWTI)/興和
  • SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%: Alcon Research
  • ZIOPTAN (tafluprost): Merck Sharp & Dohme Corp.
  • DuoTrav PQ (travoprost/timolol): Novartis/Alcon Research
  • TRAVATAN Z (travoprost ophthalmic solution) 0.004%:Alcon Research, a Novartis company
  • LUMIGAN 0.01% (bimatoprost ophthalmic solution): Allergan

第11章 新薬

  • キークロスコンペティション
  • Bimatoprost SR (Sustained-Release):Allergan
    • 医薬品概要
    • 規制のマイルストーン
    • 臨床動向
    • 安全性と有効性
    • 製品プロファイル
  • PDP-716:Sun Pharma Advanced Research Company Limited (SPARC)
  • PRO-12:Laboratorios Sophia S.A de C.V.
  • Brinzolamide Ophthalmic Suspension 1%:Perrigo Company
  • Trabodenoson:Inoteck
  • DE-130A (latanoprost):参天製薬
  • CKD-351:Chong Kun Dang Pharmaceutical
  • OTX-TP (Travoprost):Ocular Therapeutix
  • Sepetaprost (DE-126/ONO-9054):Santen Inc./小野薬品工業

12章 開放隅角緑内障(OAG):主要7カ国の市場分析

  • 主な調査結果
  • 主要7カ国の市場規模
  • 主要7カ国の市場規模:治療薬別

第13章 米国の開放隅角緑内障(OAG)市場の見通し

  • 市場規模
  • 市場規模:治療薬別

第14章 EU5カ国の開放隅角緑内障(OAG)市場の見通し

  • ドイツ
    • 市場規模
    • 市場規模:治療薬別
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 日本

第15章 日本の開放隅角緑内障(OAG)市場の見通し

  • 市場規模
  • 市場規模:治療薬別

第16章 市場成長要因

第17章 市場の障壁

第18章 付録

第19章 DelveInsightのサービス内容

第20章 免責事項

第21章 DelveInsightについて

図表

List of Tables

Table 1 Clinical Stages of Primary Open-Angle Glaucoma

Table 2 Two Classes of Primary Open-Angle Glaucoma (POAG) Mutations

Table 3 Total Prevalence of Glaucoma in the 7MM (2017-2028)

Table 4 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM (2017-2028)

Table 5 Total Prevalence of Glaucoma in the United States (2017-2028)

Table 6 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the US (2017-2028)

Table 7 Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in the US (2017-2028)

Table 8 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States(2017-2028)

Table 9 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States (2017-2028)

Table 10 Total Prevalence of Glaucoma in Germany (2017-2028)

Table 11 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Germany (2017-2028)

Table 12 Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2028)

Table 13 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2028)

Table 14 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2028)

Table 15 Total Prevalence of Glaucoma in France (2017-2028)

Table 16 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in France (2017-2028)

Table 17 Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2028)

Table 18 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2028)

Table 19 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2028)

Table 20 Total Prevalence of Glaucoma in the Italy (2017-2028)

Table 21 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Italy (2017-2028)

Table 22 Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2028)

Table 23 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2028)

Table 24 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2028)

Table 25 Total Prevalence of Glaucoma in the Spain (2017-2028)

Table 26 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Spain (2017-2028)

Table 27 Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2028)

Table 28 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2028)

Table 29 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2028)

Table 30 Total Prevalence of Glaucoma in the United Kingdom (2017-2028)

Table 31 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the United Kingdom (2017-2028)

Table 32 Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom (2017-2028)

Table 33 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom (2017-2028)

Table 34 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom (2017-2028)

Table 35 Total Prevalence of Glaucoma in Japan (2017-2028)

Table 36 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Japan (2017-2028)

Table 37 Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2028)

Table 38 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2028)

Table 39 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2028)

Table 40 Suggestions for the Medical Management of Primary Open-Angle Glaucoma and Ocular Hypertension

Table 41 Pharmacological Agents for Management of Primary Open-Angle Glaucoma

Table 42 General Guidelines for Postoperative Management of Patients Following Argon Laser Trabeculoplasty

Table 43 List of Marketed Drugs and their Relative Therapeutic Classes

Table 44 ROCKLATAN, Clinical Trial Description, 2019

Table 45 Rhopressa, Clinical Trial Description, 2019

Table 46 EYBELIS Ophthalmic Solution 0.002%, Clinical Trial Description, 2019

Table 47 VYZULTA, Clinical Trial Description, 2019

Table 48 DE-111; Clinical Trial Description, 2019

Table 49 Glanatec; Clinical Trial Description, 2019

Table 50 SIMBRINZA, Clinical Trial Description, 2019

Table 51 Zioptan, Clinical Trial Description, 2019

Table 52 DuoTrav, Clinical Trial Description, 2019

Table 53 TRAVATAN Z, Clinical Trial Description, 2019

Table 54 LUMIGAN 0.01%, Clinical Trial Description, 2019

Table 55 Emerging Keycross Competition

Table 56 Bimatoprost SR (Sustained-Release) Clinical Trial Description, 2019

Table 57 PDP - 716, Clinical Trial Description, 2019

Table 58 PRO-122, Clinical Trial Description, 2019

Table 59 Brinzolamide Ophthalmic Suspension 1%, Clinical Trial Description, 2019

Table 60 Trabodenoson (INO-8875), Clinical Trial Description, 2019

Table 61 DE-130A (latanoprost), Clinical Trial Description, 2019

Table 62 CKD-351, Clinical Trial Description, 2019

Table 63 OTX-TP (Travoprost), Clinical Trial Description, 2019

Table 64 DE-126, Clinical Trial Description, 2019

Table 65 NCX 470, Clinical Trial Description, 2019

Table 66 SYL040012 (bamosiran) , Clinical Trial Description, 2019

Table 67 ENV515 Travoprost XR, Clinical Trial Description, 2019

Table 68 Nyxol (Phentolamine Mesylate), Clinical Trial Description, 2019

Table 69 POLAT-001, Clinical Trial Description, 2019

Table 70 Market Size of Open-Angle Glaucoma in 7MM in USD Million (2017-2028)

Table 71 Market Size of Open-Angle Glaucoma by therapies in the 7MM, in USD Million (2017-2028)

Table 72 Currently Prescribed Classes and their Side-Effects

Table 73 The US Market Size of Open-Angle Glaucoma in USD Million (2017-2028)

Table 74 Market Size of Open-Angle Glaucoma by therapies in the US, in USD Million (2017-2028)

Table 75 Germany Market Size of Open-Angle Glaucoma in USD Million (2017-2028)

Table 76 Market Size of Open-Angle Glaucoma by therapies in Germany, in USD Million (2017-2028)

Table 77 France Market Size of Open-Angle Glaucoma in USD Million (2017-2028)

Table 78 Market Size of Open-Angle Glaucoma by therapies in France, in USD Million (2017-2028)

Table 79 Italy Market Size of Open-Angle Glaucoma in USD Million (2017-2028)

Table 80 Market Size of Open-Angle Glaucoma by therapies in Italy, in USD Million (2017-2028)

Table 81 Spain Market Size of Open-Angle Glaucoma in USD Million (2017-2028)

Table 82 Market Size of Open-Angle Glaucoma by therapies in Spain, in USD Million (2017-2028)

Table 83 The UK Market Size of Open-Angle Glaucoma in USD Million (2017-2028)

Table 84 Market Size of Open-Angle Glaucoma by therapies in the UK, in USD Million (2017-2028)

Table 85 Japan Market Size of Open-Angle Glaucoma in USD Million (2017-2028)

Table 86 Market Size of Open-Angle Glaucoma by therapies in Japan, in USD Million (2017-2028)

List of Figures

Figure 1 Open-Angle in Glaucoma

Figure 2 Development of Glaucoma

Figure 3 Classification of Open-Angle Glaucoma

Figure 4 Symptoms of Open-Angle Glaucoma

Figure 5 Risk Factors Associated with Open-Angle Glaucoma

Figure 6 Factors Contributing to the Pathophysiology of Glaucomatous Neurodegeneration

Figure 7 Pathophysiology of Primary Open-Angle Glaucoma

Figure 8 Diagnosis of Primary Open-Angle Glaucoma (POAG)

Figure 9 Glaucoma Assessment (Optic Nerve)

Figure 10 Total Prevalence of Glaucoma in the 7MM (2017-2028)

Figure 11 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM (2017-2028)

Figure 12 Total Prevalence of Glaucoma in the United States (2017-2028)

Figure 13 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the US (2017-2028)

Figure 14 Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in the US (2017-2028)

Figure 15 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States (2017-2028)

Figure 16 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States (2017-2028)

Figure 17 Total Prevalence of Glaucoma in Germany (2017-2028)

Figure 18 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Germany (2017-2028)

Figure 19 Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2028)

Figure 20 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2028)

Figure 21 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2028)

Figure 22 Total Prevalence of Glaucoma in France (2017-2028)

Figure 23 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in France (2017-2028)

Figure 24 Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2028)

Figure 25 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2028)

Figure 26 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2028)

Figure 27 Total Prevalence of Glaucoma in Italy (2017-2028)

Figure 28 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Italy (2017-2028)

Figure 29 Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2028)

Figure 30 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2028)

Figure 31 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2028)

Figure 32 Total Prevalence of Glaucoma in Spain (2017-2028)

Figure 33 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Spain (2017-2028)

Figure 34 Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2028)

Figure 35 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2028)

Figure 36 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2028)

Figure 37 Total Prevalence of Glaucoma in the United Kingdom (2017-2028)

Figure 38 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the United Kingdom (2017-2028)

Figure 39 Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom (2017-2028)

Figure 40 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom (2017-2028)

Figure 41 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom (2017-2028)

Figure 42 Total Prevalence of Glaucoma in Japan (2017-2028)

Figure 43 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Japan (2017-2028)

Figure 44 Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2028)

Figure 45 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2028)

Figure 46 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2028)

Figure 47 Treatment of primary open-angle glaucoma: Medical treatment

Figure 48 Treatment Algorithm for Open-Angle Glaucoma

Figure 49 Unmet Needs of Open-Angle Glaucoma

Figure 50 Factors which can influence Patients Quality of Life (QoL)

Figure 51 Market Size of Open-Angle Glaucoma in the 7MM in USD Million (2017-2028)

Figure 52 Market Size of Open-Angle Glaucoma by therapies in the 7MM, in USD Million (2017-2028)

Figure 53 Market Size of Open-Angle Glaucoma in the US, USD Millions (2017-2028)

Figure 54 Market Size of Open-Angle Glaucoma by therapies in the United States, in USD Million (2017-2028)

Figure 55 Market Size of Open-Angle Glaucoma in Germany, USD Millions (2017-2028)

Figure 56 Market Size of Open-Angle Glaucoma by therapies in Germany, in USD Million (2017-2028)

Figure 57 Market Size of Open-Angle Glaucoma in France, USD Millions (2017-2028)

Figure 58 Market Size of Open-Angle Glaucoma by therapies in France, in USD Million (2017-2028)

Figure 59 Market Size of Open-Angle Glaucoma in Italy, USD Millions (2017-2028)

Figure 60 Market Size of Open-Angle Glaucoma by therapies in Italy in USD Million (2017-2028)

Figure 61 Market Size of Open-Angle Glaucoma in Spain, USD Millions (2017-2028)

Figure 62 Market Size of Open-Angle Glaucoma by therapies in Spain in USD Million (2017-2028)

Figure 63 Market Size of Open-Angle Glaucoma in the UK, USD Millions (2017-2028)

Figure 64 Market Size of Open-Angle Glaucoma by therapies in the UK in USD Million (2017-2028)

Figure 65 Market Size of Open-Angle Glaucoma in Japan, USD Millions (2017-2028)

Figure 66 Market Size of Open-Angle Glaucoma by therapies in Japan in USD Million (2017-2028)

Figure 67 Market Drivers

Figure 68 Market Barriers

目次
Product Code: DIMI0151

DelveInsight's Open-angle glaucoma (OAG) - Market Insights, Epidemiology, and Market Forecast-2028 (7MM) report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of OAG in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of OAG from 2017 to 2028 segmented by the seven major markets.

The current treatment management of the disease focuses on lowering intraocular pressure (IOP) with the current class of drugs, like prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. However, these treatments have not helped all patients. Some patients continue to experience deterioration in the optic nerve even though their IOPs are within the normal range. Besides these pharmacological treatment measurements, incisional surgery, laser surgery, and medication are also preferred.

There are several unmet needs in the management of this indication and more than a dozen companies have shifted their focus towards this therapeutic area. To name a few, Allergan, Sun Pharma, Laboratorios Sophia, Perrigo Company, Inotek Pharmaceutical, Santen Pharmaceutical, Chong Kun Dang Pharmaceutical, Sylentis, Envisia Therapeutics, Santen/Ono Pharmaceutical, Nicox Ophthalmics and others.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Open-angle glaucoma - Disease Understanding and Treatment Algorithm

Open-angle glaucoma (OAG) is a progressive form of glaucoma in which the channel formed between the iris and the cornea remains open and tissue changes along the channel, which gradually reduces the drainage of the aqueous humor through the trabecular meshwork of the eye's anterior chamber. It is the most common form of glaucoma which accounts for majority of the glaucoma cases. The term "Open-Angle" refers to the angle where the iris meets the cornea and is as wide and open as it should be. OAG is mainly caused by the slow clogging of the drainage canals, resulting in increased eye pressure.

In OAG, there are characteristic optic nerve changes (damage) associated with open angles (the area between the iris and cornea) and elevated eye pressure. The risk factors associated with open-angle glaucoma include elevated intraocular pressure (IOP), age >60 years, genetic predisposition, certain eye characteristics (such as a pupillary defect, thin cornea, myopia), low educational status, smoking, African descent, and visual problems (such as ocular hypertension, larger horizontal or vertical cup disc ratio, greater Humphrey visual field pattern deviation, asymmetries in the visual field, and IOP).

OAG is primarily divided into two subtypes, i.e., Primary OAG and Secondary OAG. The risk factors of OAG are divided into four categories, general factors, ocular factors, nonocular factors, and ocular hypertension.

DelveInsight's OAG market report gives a thorough understanding of the OAG by including details, such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms.

Open-angle glaucoma - Epidemiology

The Open-angle glaucoma (OAG) epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL). This part of the DelveInsight's report also provides the diagnosed patient pool and their trends along with undertaken assumptions.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalence of Glaucoma in the 7MM, Total Diagnosed Prevalent Population of Open-Angle Glaucoma , Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma, Age - Specific Diagnosed Prevalence of Open-Angle Glaucoma and Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma] scenario of OAG in the 7MM Countries covering United States, EU5 countries (Germany, Spain, Italy, France, and United Kingdom), and Japan from 2017 to 2028.

As per DelveInsight's analysis, a higher percentage of diagnosed prevalence of OAG was observed for females, in comparison to males, in all the 7MM countries. DelveInsight's analysts have assessed that the total prevalent population of Glaucoma in the 7MM was 9,819,080 in 2017. In addition to this it was also assessed that among those with glaucoma in the 7MM, more than 8.5 million were diagnosed with OAG. DelveInsight's estimate suggests that the United States witnessed highest number of cases with OAG, as compared to other 7MM countries. As per DelveInsight's estimates, the country accounted for approximately 2,749,378 cases in 2017.

Among the EU-5 countries, Germany accounted for the highest number of glaucoma cases in 2017, which was observed to be equivalent to more than 25% of the total affected population in this region. The number of cases for glaucoma was observed to be 1,041,889 in the country for 2017. However, Spain accounted for the lowest number of glaucoma cases in 2017, which was approximately 13.33% of the total affected population of EU-5 countries. According to the DelveInsight's analysts, Japan accounted for second-highest number of OAG patients, i.e., 28.79% of the total OAG population in the 7MM countries. According to DelveInsight's assessment, it has been observed that OAG prevalence varied across the 7MM countries, based on age-specific prevalence of the disease. For instance, the highest proportion was observed in 70-79 years age group in the US, while in the EU-5 countries, people aged ≥80 years accounted for the maximum patient pool. In contrast, middle age population aged 40-49 years contributed highest patient pool in Japan.

Open-angle glaucoma - Drug Chapters

This segment of the Open-angle glaucoma (OAG) report encloses the detailed analysis of marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The treatment and market of OAG are dependent on class of drugs, like prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. In emerging therapies following drugs are there Bimatoprost SR (Allergan), PDP - 716 (Sun Pharma), Trabodenoson (Inotek Pharmaceuticals), DE-30A (Santen), and others.

Allergan's drug candidate, Bimatoprost SR is a biodegradable sustained-release implant, which is currently under development in phase III for the treatment of OAG and ocular hypertension. The solid, rod-shaped implant consists of the prostaglandin analog (PGA) bimatoprost within the company's Novadur platform for drug delivery. In July 2019, the United States Food and Drug Administration (US FDA) accepted Allergan's new drug application for bimatoprost sustained-release in patients with OAG or ocular hypertension. The FDA is expected to take action on the NDA by the end of the first half of 2020.

PDP - 716 is the once-a-day formulation of Brimonidine developed using SPARC's TearActTM Technology for treatment of Glaucoma by Sun Pharma. PDP - 716 provides dosing convenience to patients compared to a currently marketed product that requires thrice-a-day dosing. SPARC initiated the pivotal Phase III study for PDP - 716 in the USA. The study is randomizing patients and is expected to be completed by Q4 FY 2019-20. SPARC is in discussion with potential partners for licensing of PDP - 716.

Inotek Pharmaceuticals is another pharma key player who is developing novel formulation for treatment of OAG. Trabodenoson (INO-8875) is a drop-administered drug candidate developed by Inotek Pharmaceuticals. It is a monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination that includes trabodenoson plus latanoprost, which is referred to as FDC (Fixed-Dose Combination) product.

Among all these mentioned companies Santen is constantly working to meet the unmet needs of the OAG. Two of its products are in pipeline (phase II and Phase III), i.e., DE-130A and Sepetaprost (ONO-9054). DE-130A is an ophthalmic emulsion of a prostaglandin F2α derivative, for the treatment of glaucoma and ocular hypertension. This product is in phase III clinical development stage. Santen recently initiated the phase III trial in Europe and Asia. On the other hand, ONO-9054 is a once-daily prostaglandin eye drop drug product with a novel, dual-mode of action that activates both FP and EP3 receptors (both FP and EP3 receptors are prostaglandin receptors). ONO-9054 is expected to show a superior intraocular pressure (IOP) lowering effect compared to FP receptor agonists.

The company has completed the Phase II clinical trial of ONO-9054 for the treatment of glaucoma and ocular hypertension in the US. In the future, Santen will seek manufacturing and marketing approval for ONO-9054 on a worldwide basis. There are several other product in the clinical development for the treatment of OAG.

Open-angle glaucoma - Market Outlook

The Open-angle glaucoma (OAG) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.

This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

As per the assessment by DelveInsight's analysts, it has been observed that the market size of OAG was observed to be USD 3,316.70 million in in 2017, in the 7MM. For OAG, the market size was accessed on the the bases of currently prescribed treatment option, i.e., Prostaglandin analogs, Beta-blockers, Carbonic anhydrase inhibitors, Miotics, Alpha-2-selective adrenergic agonists, and other treatment regimens which remains the mainstay of OAG therapeutic market, and these include the specific approved therapies for each of these classes. In addition, the therapeutic market of OAG shall significantly rise in coming years, owing to the expected launch of targeted therapies. Among all the seven major markets, the United States covers the major market share that accounts for 41.01% of the 7MM. In 2017, the market size was accessed to be USD 1,360.29 million in the country.

The products which are anticipated to be launched in the 7MM include Bimatoprost SR (Sustained-Release; Allergan), DE-117 (omidenepag isopropyl; Santen Pharmaceutical); PRO-122 (Laboratorios Sophia); PDP - 716 (Brimonidine; Sun Pharma); Sepetaprost (DE-126/ONO-9054: Santen/Ono Pharmaceutical); NCX 470 (Nicox Ophthalmics) and Nyxol (Phentolamine Mesylate: Ocuphire Pharma). However, in addition to this, it is anticipated that Aerie Pharma with its two products ROCKLATAN and RHOPRESSA will definitely enter the open-angle glaucoma market of Europe. Besides this Sun Pharma Advanced Research Company (SPARC) is also expecting the launch of its product PDP - 716 (Brimonidine). In addition to this, a product named), DE-130A (of Santen Pharmaceutical is also anticipated to be launched in the European countries. ROCKLATAN and RHOPRESSA are approved in the US and recently Aerie pharma received a positive opinion from the CHMP. This positive opinion will help in the smooth launch of RHOPRESSA (under the name RHOKIINSA).

Some of these products have completed the late clinical stages of development, while others are in ongoing late clinical development stages. These drug candidates have shown very promising results and it has been anticipated by DelveInsight's analysts that completion of clinical development and launch of these products in the market, might increase the market share of these companies, and besides this, patients of OAG will have better management practices. According to our assessment, potential emerging candidates shall launch in the upcoming years of the forecast period [2019-2028], and with their anticipated launch, the market size of open-angle glaucoma will also experience significant growth.

Open-angle glaucoma (OAG) - Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allowing the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of OAG market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world and expected the launch of emerging therapies during the forecast period of 2019-2028. Companies across the globe are thoroughly working toward the development of new treatment therapies for chronic wounds.

To meet the unmet need of the market and to provide better versions of current treatment practices, several companies have shifted their focus toward this therapeutic area, and several therapies are expected to enter the treatment market of OAG during our forecast period, including In emerging therapies following drugs are there Bimatoprost SR (Allergan), PDP - 716 (Sun Pharma.), Trabodenoson (Inotek Pharmaceuticals), DE-130A (Santen), and others.

Open-angle glaucoma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Open-angle glaucoma Report Key Strengths

  • 10 Years Forecast
  • 7MM Countries Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Open-angle glaucoma Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Open-angle glaucoma market
  • Organize sales and marketing efforts by identifying the best opportunities for Open-angle glaucoma market
  • To understand the future market competition in the Open-angle glaucoma market.

Table of Contents

1. Key Insights

2. Open-Angle Glaucoma (OAG): Market Overview at a Glance

  • 2.1. Total Market Share (%) Distribution of OAG in 2017
  • 2.2. Total Market Share (%) Distribution of OAG in 2028

3. Open-Angle Glaucoma: Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Classification of Open-Angle Glaucoma
  • 3.3. Signs and Symptoms of Open-Angle Glaucoma
  • 3.4. Risk Factors of Open-Angle Glaucoma
    • 3.4.1. General
    • 3.4.2. Ocular
    • 3.4.3. Nonocular
    • 3.4.4. Ocular Hypertension
  • 3.5. Pathophysiology of Open-Angle Glaucoma
  • 3.6. Genes Involved in Primary Open-Angle Glaucoma
    • 3.6.1. Myocilin (MYOC, OMIM #601652)
    • 3.6.2. Optineurin (OPTN, OMIM #602432)
    • 3.6.3. TANK-binding Kinase-1 (TBK1)
    • 3.6.4. WD-repeat domain 36 (WDR36, OMIM 609669)
  • 3.7. Diagnosis of Open-Angle Glaucoma
    • 3.7.1. Diagnosis of Primary Open-Angle Glaucoma
    • 3.7.2. Diagnosis of Secondary Open-Angle Glaucoma

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalence of Glaucoma in the 7MM
  • 4.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM

5. United States Epidemiology

  • 5.1. Assumptions and Rationale
  • 5.2. Total Prevalence of Glaucoma in the United States
  • 5.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the United States
  • 5.4. Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States
  • 5.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States
  • 5.6. Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States

6. EU5 Epidemiology

  • 6.1. Germany Epidemiology
    • 6.1.1. Assumptions and Rationale
    • 6.1.2. Total Prevalence of Glaucoma in Germany
    • 6.1.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Germany
    • 6.1.4. Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany
    • 6.1.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany
    • 6.1.6. Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany
  • 6.2. France Epidemiology
    • 6.2.1. Assumptions and rationale
    • 6.2.2. Total Prevalence of Glaucoma in France
    • 6.2.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in France
    • 6.2.4. Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in France
    • 6.2.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in France
    • 6.2.6. Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in France
  • 6.3. Italy Epidemiology
    • 6.3.1. Assumptions and Rationale
    • 6.3.2. Total Prevalence of Glaucoma in Italy
    • 6.3.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Italy
    • 6.3.4. Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy
    • 6.3.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy
    • 6.3.6. Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy
  • 6.4. Spain Epidemiology
    • 6.4.1. Assumptions and Rationale
    • 6.4.2. Total Prevalence of Glaucoma in Spain
    • 6.4.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Spain
    • 6.4.4. Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain
    • 6.4.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain
    • 6.4.6. Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain
  • 6.5. United Kingdom Epidemiology
    • 6.5.1. Assumptions and Rationale
    • 6.5.2. Total Prevalence of Glaucoma in the United Kingdom
    • 6.5.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the United Kingdom
    • 6.5.4. Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom
    • 6.5.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom
    • 6.5.6. Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom

7. Japan Epidemiology

  • 7.1. Assumptions and Rationale
    • 7.1.1. Total Prevalence of Glaucoma in Japan
    • 7.1.2. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Japan
    • 7.1.3. Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan
    • 7.1.4. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan
    • 7.1.5. Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Treatment Algorithm for Open-Angle Glaucoma
  • 8.2. Treatment and Management for Open-Angle Glaucoma
    • 8.2.1. Basis for Treatment
    • 8.2.2. Available Treatment Options
    • 8.2.3. Medical (Pharmaceutical) Treatment
    • 8.2.4. Laser Trabeculoplasty
    • 8.2.5. Surgery
  • 8.3. Prognosis and Follow-up of Open-Angle Glaucoma
    • 8.3.1. Prognosis
    • 8.3.2. Frequency of Follow-up
    • 8.3.3. Therapy Modification
    • 8.3.4. Effectiveness of Treatment
  • 8.4. Management of Patients with Severe, Irreversible Vision Loss

9. Unmet Needs

10. Marketed Products

  • 10.1. Marketed Products And Their Relative Therapeutic Classes
  • 10.2. ROCKLATAN: Aerie Pharmaceuticals
    • 10.2.1. Product Description
    • 10.2.2. Regulatory Milestones
    • 10.2.3. Clinical Development
    • 10.2.4. Safety and efficacy
    • 10.2.5. Adverse Reaction
    • 10.2.6. Product Profile
  • 10.3. Rhopressa: Aerie Pharmaceuticals
    • 10.3.1. Product Description
    • 10.3.2. Regulatory Milestones
    • 10.3.3. Clinical Development
    • 10.3.4. Safety and efficacy
    • 10.3.5. Product Profile
  • 10.4. XELPROS (latanoprost ophthalmic emulsion) 0.005%: Sun Pharma Advanced Research Company Limited
    • 10.4.1. Product Description
    • 10.4.2. Regulatory Milestones
    • 10.4.3. Clinical Development
    • 10.4.4. Product Profile
  • 10.5. EYBELIS Ophthalmic Solution 0.002% (DE-117, Omidenepag isopropyl): Santen Pharmaceutical/ Ube Industries
    • 10.5.1. Product Description
    • 10.5.2. Regulatory Milestones
    • 10.5.3. Clinical Development
    • 10.5.4. Safety and efficacy
    • 10.5.5. Product Profile
  • 10.6. VYZULTA: Bausch and Lomb
    • 10.6.1. Product Description
    • 10.6.2. Regulatory Milestones
    • 10.6.3. Clinical Development
    • 10.6.4. Safety and efficacy
    • 10.6.5. Product Profile
  • 10.7. TAPCOM/ DE-111 (Tafluprost/timolol maleate): Santen Pharmaceutical Co., Ltd.
    • 10.7.1. Product Description
    • 10.7.2. Regulatory Milestones
    • 10.7.3. Clinical Development
    • 10.7.4. Product Profile
  • 10.8. GLANATEC: D.Western Therapeutics Institute (DWTI)/Kowa LTD.
    • 10.8.1. Product Description
    • 10.8.2. Regulatory Milestones
    • 10.8.3. Clinical Development
    • 10.8.4. Safety and Efficacy
    • 10.8.5. Product Profile
  • 10.9. SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%: Alcon Research
    • 10.9.1. Product Description
    • 10.9.2. Regulatory Milestones
    • 10.9.3. Clinical Development
    • 10.9.4. Safety and efficacy
    • 10.9.5. Product Profile
  • 10.10. ZIOPTAN (tafluprost): Merck Sharp & Dohme Corp.
    • 10.10.1. Product Description
    • 10.10.2. Regulatory Milestones
    • 10.10.3. Clinical Development
    • 10.10.4. Safety and efficacy
    • 10.10.5. Product Profile
  • 10.11. DuoTrav PQ (travoprost/timolol): Novartis/Alcon Research
    • 10.11.1. Product Description
    • 10.11.2. Regulatory Milestones
    • 10.11.3. Clinical Development
    • 10.11.4. Safety and efficacy
    • 10.11.5. Product Profile
  • 10.12. TRAVATAN Z (travoprost ophthalmic solution) 0.004%: Alcon Research, a Novartis company
    • 10.12.1. Product Description
    • 10.12.2. Regulatory Milestones
    • 10.12.3. Clinical Development
    • 10.12.4. Safety and efficacy
    • 10.12.5. Product Profile
  • 10.13. LUMIGAN 0.01% (bimatoprost ophthalmic solution): Allergan
    • 10.13.1. Product Description
    • 10.13.2. Regulatory Milestones
    • 10.13.3. Clinical Development
    • 10.13.4. Product Profile

11. Emerging Therapies

  • 11.1. Key Cross Competition
  • 11.2. Bimatoprost SR (Sustained-Release): Allergan
    • 11.2.1. Product Description
    • 11.2.2. Other Developmental Activities
    • 11.2.3. Clinical Development
    • 11.2.4. Safety and Efficacy
    • 11.2.5. Product Profile
  • 11.3. PDP-716: Sun Pharma Advanced Research Company Limited (SPARC)
    • 11.3.1. Product Description
    • 11.3.2. Other Developmental Activities
    • 11.3.3. Clinical Development
    • 11.3.4. Safety and Efficacy
    • 11.3.5. Product Profile
  • 11.4. PRO-12: Laboratorios Sophia S.A de C.V.
    • 11.4.1. Product Description
    • 11.4.2. Clinical Development
    • 11.4.3. Safety and Efficacy
    • 11.4.4. Product Profile
  • 11.5. Brinzolamide Ophthalmic Suspension 1%: Perrigo Company
    • 11.5.1. Product Description
    • 11.5.2. Clinical Development
    • 11.5.3. Product Profile
  • 11.6. Trabodenoson: Inoteck
    • 11.6.1. Product Description
    • 11.6.2. Other Developmental Activities
    • 11.6.3. Clinical Development
    • 11.6.4. Safety and Efficacy
    • 11.6.5. Product Profile
  • 11.7. DE-130A (latanoprost): Santen Pharmaceutical
    • 11.7.1. Product Description
    • 11.7.2. Clinical Development
    • 11.7.3. Product Profile
  • 11.8. CKD-351: Chong Kun Dang Pharmaceutical
    • 11.8.1. Product Description
    • 11.8.2. Other Developmental Activities
    • 11.8.3. Clinical Development
    • 11.8.4. Product Profile
  • 11.9. OTX-TP (Travoprost): Ocular Therapeutix
    • 11.9.1. Product Description
    • 11.9.2. Other Developmental Activities
    • 11.9.3. Clinical Development
    • 11.9.4. Product Profile
  • 11.10. Sepetaprost (DE-126/ONO-9054): Santen Inc./Ono Pharmaceutical
    • 11.10.1. Product Description
    • 11.10.2. Other Development Activities
    • 11.10.3. Clinical Development
    • 11.10.4. Product Profile
  • 11.11. NCX 470: Nicox Ophthalmics
    • 11.11.1. Product Description
    • 11.11.2. Other Developmental Activities
    • 11.11.3. Clinical Development
    • 11.11.4. Product Profile
  • 11.12. Bamosiran (SYL040012): Sylentis
    • 11.12.1. Product Description
    • 11.12.2. Other Developmental Activities
    • 11.12.3. Clinical Development
    • 11.12.4. Product Profile
  • 11.13. ENV515 (Travoprost XR): Envisia Therapeutics
    • 11.13.1. Product Description
    • 11.13.2. Other Developmental Activities
    • 11.13.3. Clinical Development
    • 11.13.4. Product Profile
  • 11.14. Nyxol (Phentolamine Mesylate): Ocuphire Pharma
    • 11.14.1. Product Description
    • 11.14.2. Clinical Development
    • 11.14.3. Product Profile
  • 11.15. POLAT-001: Peregrine Ophthalmic
    • 11.15.1. Product Description
    • 11.15.2. Other Developmental Activities
    • 11.15.3. Clinical Development
    • 11.15.4. Product Profile

12. Open-Angle Glaucoma (OAG): 7MM Market Analysis

  • 12.1. Key Findings
    • 12.1.1. Market Size of Open-Angle Glaucoma in 7MM
    • 12.1.2. Market Size of Open-Angle Glaucoma by Therapies in the 7MM

13. United States: Market Outlook

  • 13.1. United States Market Size
    • 13.1.1. Total Market size of Open-Angle Glaucoma in the United States
    • 13.1.2. Market Size of Open-Angle Glaucoma by Therapies in the US

14. EU-5 countries: Market Outlook

  • 14.1. Germany Market Size
    • 14.1.1. Total Market size of Open-Angle Glaucoma in Germany
    • 14.1.2. Market Size of Open-Angle Glaucoma by therapies in Germany
  • 14.2. France Market Size
    • 14.2.1. Total Market size of Open-Angle Glaucoma in France
    • 14.2.2. Market Size of Open-Angle Glaucoma by therapies in France
  • 14.3. Italy Market Size
    • 14.3.1. Total Market size of Open-Angle Glaucoma in Italy
    • 14.3.2. Market Size of Open-Angle Glaucoma by therapies in Italy
  • 14.4. Spain Market Size
    • 14.4.1. Total Market size of Open-Angle Glaucoma in Spain
    • 14.4.2. Market Size of Open-Angle Glaucoma by therapies in Spain
  • 14.5. United Kingdom Market Size
    • 14.5.1. Total Market size of Open-Angle Glaucoma in the United Kingdom
    • 14.5.2. Market Size of Open-Angle Glaucoma by therapies in the UK

15. Japan Market Outlook

  • 15.1. Japan Market Size
    • 15.1.1. Total Market size of Open-Angle Glaucoma in Japan
    • 15.1.2. Market Size of Open-Angle Glaucoma by therapies in Japan

16. Market Drivers

17. Market Barriers

18. Appendix

  • 18.1. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Back to Top